Released On
November 5, 2020

Expires On
November 4, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Allergy & Immunology, Dermatology, Pediatrics, Primary Care, Rheumatology

Topic(s)
Allergies

Scroll to the Bottom of this Information to Begin this Course

Provided by Clinical Care Options, LLC.

This educational activity is supported by educational grants from AbbVie Inc. and Pfizer Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Nursing Contact Hour

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The primary target audience for the activities includes dermatologists, immunologists, nurses, and other healthcare providers who treat patients with moderate to severe AD.

Program Overview

The goal of this initiative is to provide dermatologists and allergists with data on current and emerging therapies for moderate to severe AD that would have been presented at AAAAI 2020, RAD 2020, and AAD 2020.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Critically evaluate study results from recent trials of AD regarding treatment efficacy and safety
  • Describe how new trial data will affect/change the management of patients with AD

Faculty

Andrew F. Alexis, MD, MPH

Andrew F. Alexis, MD, MPH

Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
Director, Skin of Color Center
Mount Sinai West and Mount Sinai Morningside
New York, New York

Jonathan Silverberg, MD

Jonathan Silverberg, MD

Associate Professor, Dermatology
Director of Clinical Research
Director of Patch Testing

George Washington University School of Medicine and Health Sciences
Washington, DC

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 


Physician Continuing Medical Education Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosures of Conflicts of Interest

Faculty

Andrew F. Alexis, MD, MPH, has disclosed that he has received funds for research support from Almirall, Bristol-Myers Squibb, Cara, Celgene, Galderma, Leo, Menlo, Novartis, and Valeant (Bausch Health) and consulting fees from Beiersdorf, Bristol-Myers Squibb, Cassiopea, Celgene, Dermavant, Foamix, Galderma, Leo, L’Oreal, Menlo, Novartis, Pfizer, Sanofi-Regeneron, Scientis, UCB, Unilever, and Valeant (Bausch Health).

Jonathan Silverberg, MD, has disclosed that he has received consulting fees from AbbVie, Arena, Bluefin, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Novartis, Pfizer, RAPT, Regeneron, and Sanofi; fees for non-CME/CE services from Regeneron and Sanofi; and funds for research support from Galderma.

Staff

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME services from Salix Pharmaceuticals, Saluda Medical, and Shionogi, Inc.

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Anne Roc, PhD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Participation and Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 05, 2020, through November 04, 2021:

  1. Register online at https://www.clinicaloptions.com.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. Study the educational activity online or printed out.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

Contact Information

For CME questions please contact: skelley@clinicaloptions.com